A retrospective, international, multicenter study investigating glucose metabolism in patients with Acro resistant to 1st gen somatostatin receptor ligands (SRLs) treated with Pegvisomant (Peg) or Pasireotide LAR (Pasi)
Latest Information Update: 08 Oct 2021
At a glance
- Drugs Pasireotide (Primary) ; Pegvisomant (Primary)
- Indications Acromegaly
- Focus Therapeutic Use
Most Recent Events
- 01 Sep 2021 Results (n=40) published in the Endocrine
- 01 Feb 2021 Results published in the European Journal of Endocrinology
- 23 Jun 2020 New trial record